SOPHiA Genetics SA (SOPH) intrinsic value & 10-year financials
SOPHiA Genetics SA (SOPH) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 8 fiscal years revenue grew 20.4% a year to $77.3M, with an average return on invested capital of -249.9%.
- Graham intrinsic value
- —
- Revenue (FY2025)
- $77.3M
- Revenue growth (8-yr CAGR)
- 20.4%
- ROIC (10-yr avg)
- -249.9%
- Free cash flow (FY2025)
- -$36.5M
SOPH 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $77.3M | -$79.0M | -$1.17 | -$36.5M | -91.8% | -262.2% |
| FY2024 | $65.2M | -$62.5M | -$0.95 | -$43.1M | -102.1% | -230.8% |
| FY2023 | $62.4M | -$79.0M | -$1.22 | -$50.1M | -120.0% | -265.4% |
| FY2022 | $47.6M | -$87.4M | -$1.36 | -$74.2M | -184.7% | — |
| FY2021 | $40.5M | -$73.7M | -$1.33 | -$60.6M | -176.7% | -128.1% |
| FY2020 | $28.4M | -$39.3M | -$0.93 | -$32.2M | -131.6% | -191.6% |
| FY2019 | $25.4M | -$33.8M | — | -$33.0M | — | -421.2% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
SOPHiA GENETICS SA revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
SOPHiA GENETICS SA has historically struggled to out-earn its cost of capital, averaging just -23.6% ROIC.
SOPHiA GENETICS SA capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, SOPHiA GENETICS SA is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-38.86 per share.